aTYR PHARMA INC financial data

Symbol
LIFE on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
10240 Sorrento Valley Road, Suite 300, San Diego, California
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 2, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 731 % -7.21%
Return On Equity -56.9 % -8.59%
Return On Assets -43.9 % -3.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 67.8 M shares +27.4%
Common Stock, Shares, Outstanding 68.4 M shares +28.1%
Entity Public Float 121 M USD +56.5%
Common Stock, Value, Issued 68 K USD +28.3%
Weighted Average Number of Shares Outstanding, Basic 66.1 M shares +57.7%
Weighted Average Number of Shares Outstanding, Diluted 66.1 M shares +57.7%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 235 K USD
Research and Development Expense 46.3 M USD +6.9%
General and Administrative Expense 13.1 M USD -5.97%
Operating Income (Loss) -58.8 M USD -25.5%
Nonoperating Income (Expense) 4.84 M USD +189%
Net Income (Loss) Attributable to Parent -53.9 M USD -19.5%
Earnings Per Share, Basic -0.88 USD/shares +39.3%
Earnings Per Share, Diluted -0.88 USD/shares +39.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 6.81 M USD -67.1%
Assets, Current 96.9 M USD -18.9%
Property, Plant and Equipment, Net 5.35 M USD +3.6%
Operating Lease, Right-of-Use Asset 6 M USD -13.6%
Other Assets, Noncurrent 130 K USD -9.72%
Assets 113 M USD -17.2%
Accounts Payable, Current 4.89 M USD +23.4%
Employee-related Liabilities, Current 2.71 M USD -2.7%
Accrued Liabilities, Current 9.95 M USD +11.9%
Liabilities, Current 16 M USD +17%
Operating Lease, Liability, Noncurrent 11.7 M USD -1.87%
Accumulated Other Comprehensive Income (Loss), Net of Tax -158 K USD +36.3%
Retained Earnings (Accumulated Deficit) -484 M USD -12.6%
Stockholders' Equity Attributable to Parent 84.5 M USD -23.1%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 84.3 M USD -23.2%
Liabilities and Equity 113 M USD -17.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -22.4 M USD -3693%
Net Cash Provided by (Used in) Financing Activities 7.73 M USD -84.4%
Net Cash Provided by (Used in) Investing Activities -1.36 M USD +96.4%
Common Stock, Shares Authorized 170 M shares +100%
Common Stock, Shares, Issued 68.4 M shares +28.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -16 M USD -249%
Interest Paid, Excluding Capitalized Interest, Operating Activities 38 K USD -17.4%
Deferred Tax Assets, Valuation Allowance 108 M USD +13.1%
Deferred Tax Assets, Gross 109 M USD +12.8%
Operating Lease, Liability 12.3 M USD -4.83%
Payments to Acquire Property, Plant, and Equipment 17 K USD -98.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -53.8 M USD -20.6%
Property, Plant and Equipment, Gross 10.2 M USD +7.85%
Operating Lease, Liability, Current 629 K USD +65.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.78 M USD -6.76%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.72 M USD -12.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 6.17 M USD -7.62%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.92 M USD +7.82%
Deferred Tax Assets, Operating Loss Carryforwards 60.1 M USD +13.9%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5 M shares 0%
Unrecognized Tax Benefits 30.1 M USD +19.6%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.94 M USD +9.29%
Additional Paid in Capital 568 M USD +5.27%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 178 K USD +123%
Deferred Tax Assets, Net of Valuation Allowance 1.41 M USD -7.22%
Share-based Payment Arrangement, Expense 2.72 M USD +15.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%